AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie UTB Rollforward by Year
UTB Rollforward — Decreases for Prior Year Tax Positions ($M) ($M)
AbbVie UTB Rollforward: $18M in FY2025, down 99.0% from a year earlier.
Latest, FY2025
18
Period ended Dec 31, 2025
Change on a year earlier
-99.0%
1,741 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 14 Income Taxes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UTB Rollforward — Decreases for Prior Year Tax Positions ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18 | -99.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 1,741 | +8,190.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 21 | -36.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 33 | -46.8% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 62 | +785.7% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 7 | -66.7% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 21 | -41.7% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 36 | +1,700.0% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 2 | -71.4% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 7 | -53.3% | Form 10-K (filed 2019-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 15 | – | Form 10-K (filed 2018-02-16) ↗ |
Cite this data
StockData. (2026). AbbVie UTB Rollforward ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/utb-dec-prior
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.